RESUMEN
Cytosolic and mitochondrial human branched chain aminotransferase (hBCATc and hBCATm, respectively) play an integral role in brain glutamate metabolism. Regional increased levels of hBCATc in the CA1 and CA4 region of Alzheimer's disease (AD) brain together with increased levels of hBCATm in frontal and temporal cortex of AD brains, suggest a role for these proteins in glutamate excitotoxicity. Glutamate toxicity is a key pathogenic feature of several neurological disorders including epilepsy associated dementia, AD, vascular dementia (VaD) and dementia with Lewy bodies (DLB). To further understand if these increases are specific to AD, the expression profiles of hBCATc and hBCATm were examined in other forms of dementia including DLB and VaD. Similar to AD, levels of hBCATm were significantly increased in the frontal and temporal cortex of VaD cases and in frontal cortex of DLB cases compared to controls, however there were no observed differences in hBCATc between groups in these areas. Moreover, multiple forms of hBCATm were observed that were particular to the disease state relative to matched controls. Real-time PCR revealed similar expression of hBCATm mRNA in frontal and temporal cortex for all cohort comparisons, whereas hBCATc mRNA expression was significantly increased in VaD cases compared to controls. Collectively our results suggest that hBCATm protein expression is significantly increased in the brains of DLB and VaD cases, similar to those reported in AD brain. These findings indicate a more global response to altered glutamate metabolism and suggest common metabolic responses that might reflect shared neurodegenerative mechanisms across several forms of dementia.
Asunto(s)
Demencia Vascular/enzimología , Regulación Enzimológica de la Expresión Génica , Enfermedad por Cuerpos de Lewy/enzimología , Transaminasas/biosíntesis , Anciano , Anciano de 80 o más Años , Encéfalo/enzimología , Encéfalo/patología , Estudios de Cohortes , Demencia Vascular/genética , Demencia Vascular/patología , Femenino , Humanos , Enfermedad por Cuerpos de Lewy/genética , Enfermedad por Cuerpos de Lewy/patología , Masculino , Antígenos de Histocompatibilidad Menor/biosíntesis , Proteínas Gestacionales/biosíntesis , Transaminasas/genéticaRESUMEN
AIMS: Deposition of amyloid beta (Aß) in the brain is one of the defining abnormalities of Alzheimer's disease (AD). Phosphorylation of Aß at serine 8 (pAß) has been implicated in its aggregation in vitro and pAß level has been shown to be significantly elevated in AD. We aimed to assess the specificity of pAß for AD and have investigated associations of pAß with parenchymal and cerebrovascular accumulation of Aß, disease progression, angiotensin-converting enzyme activity and APOE genotype. METHODS: The distribution of pAß was studied by immunohistochemistry in sporadic and familial AD, pure dementia with Lewy bodies (DLB), pure vascular dementia (VaD) and age-matched controls. Soluble and insoluble (guanidine-extractable) pAß level was measured by enzyme-linked immunosorbent assay (ELISA) in the midfrontal and parahippocampal cortex in sporadic AD (n = 20, 10 with Braak tangle stages of III-IV and 10 of stages V-VI), DLB (n = 10), VaD (n = 10) and age-matched controls (n = 20). RESULTS: We found pAß to be associated with only a subset of Aß plaques and vascular deposits in sporadic and familial AD, with absent or minimal immunohistochemically detectable pAß in control, DLB and VaD brains. In both brain regions, insoluble pAß level was significantly elevated only in advanced AD (Braak tangle stage of V or VI) and in the parahippocampus soluble and insoluble pAß level increased with the number of APOE ε4 alleles. CONCLUSIONS: These results indicate that pAß accumulation in the parenchyma and vasculature is largely restricted to late-stage AD (Braak tangle stage V-VI).
Asunto(s)
Enfermedad de Alzheimer/metabolismo , Péptidos beta-Amiloides/metabolismo , Demencia Vascular/metabolismo , Demencia/metabolismo , Anciano , Anciano de 80 o más Años , Enfermedad de Alzheimer/genética , Enfermedad de Alzheimer/patología , Apolipoproteínas E/genética , Demencia/patología , Demencia Vascular/patología , Humanos , Cuerpos de Lewy , Neocórtex/metabolismo , Neocórtex/patología , Fosforilación , Serina/metabolismo , Índice de Severidad de la EnfermedadRESUMEN
Little is known about the contributors and physiological responses to white matter hypoperfusion in the human brain. We previously showed the ratio of myelin-associated glycoprotein to proteolipid protein 1 in post-mortem human brain tissue correlates with the degree of ante-mortem ischaemia. In age-matched post-mortem cohorts of Alzheimer's disease (n = 49), vascular dementia (n = 17) and control brains (n = 33) from the South West Dementia Brain Bank (Bristol), we have now examined the relationship between the ratio of myelin-associated glycoprotein to proteolipid protein 1 and several other proteins involved in regulating white matter vascularity and blood flow. Across the three cohorts, white matter perfusion, indicated by the ratio of myelin-associated glycoprotein to proteolipid protein 1, correlated positively with the concentration of the vasoconstrictor, endothelin 1 (P = 0.0005), and negatively with the concentration of the pro-angiogenic protein, vascular endothelial growth factor (P = 0.0015). The activity of angiotensin-converting enzyme, which catalyses production of the vasoconstrictor angiotensin II was not altered. In samples of frontal white matter from an independent (Oxford, UK) cohort of post-mortem brains (n = 74), we confirmed the significant correlations between the ratio of myelin-associated glycoprotein to proteolipid protein 1 and both endothelin 1 and vascular endothelial growth factor. We also assessed microvessel density in the Bristol (UK) samples, by measurement of factor VIII-related antigen, which we showed to correlate with immunohistochemical measurements of vessel density, and found factor VIII-related antigen levels to correlate with the level of vascular endothelial growth factor (P = 0.0487), suggesting that upregulation of vascular endothelial growth factor tends to increase vessel density in the white matter. We propose that downregulation of endothelin 1 and upregulation of vascular endothelial growth factor in the context of reduced ratio of myelin-associated glycoprotein to proteolipid protein 1 are likely to be protective physiological responses to reduced white matter perfusion. Further analysis of the Bristol cohort showed that endothelin 1 was reduced in the white matter in Alzheimer's disease (P < 0.05) compared with control subjects, but not in vascular dementia, in which endothelin 1 tended to be elevated, perhaps reflecting abnormal regulation of white matter perfusion in vascular dementia. Our findings demonstrate the potential of post-mortem measurement of myelin proteins and mediators of vascular function, to assess physiological and pathological processes involved in the regulation of cerebral perfusion in Alzheimer's disease and vascular dementia.
Asunto(s)
Enfermedad de Alzheimer/patología , Encéfalo/patología , Demencia Vascular/patología , Fibras Nerviosas Mielínicas/fisiología , Anciano , Anciano de 80 o más Años , Estudios de Cohortes , Endotelina-1/metabolismo , Factor VIII/metabolismo , Femenino , Humanos , Masculino , Persona de Mediana Edad , Glicoproteína Asociada a Mielina/metabolismo , Fibras Nerviosas Mielínicas/patología , Peptidil-Dipeptidasa A/metabolismo , Factor A de Crecimiento Endotelial Vascular/metabolismoRESUMEN
Epidemiological data associate hypertension with a predisposition to Alzheimer's disease (AD), and a number of postmortem and in vivo studies also demonstrate that hypertension increases amyloid-ß (Aß) pathology. In contrast, anti-hypertensive medications reportedly improve cognition and decrease the risk of AD, while certain classes of anti-hypertensive drugs are associated with decreased AD-related pathology. We investigated the effects of hypertension and anti-hypertensive treatment on Aß plaque load in postmortem frontal cortex in AD. Aß load was significantly increased in hypertensive (nâ=â20) relative to normotensive cases (nâ=â62) and was also significantly higher in treated (nâ=â9) than untreated hypertensives (nâ=â11). We then looked into mechanisms by which hypertension and treatment might increase Aß load, focusing on Aß-synthesizing enzymes, ß- and γ-secretase, and Aß-degrading enzymes, angiotensin-converting enzyme (ACE), insulin-degrading enzyme (IDE) and neprilysin. ACE and IDE protein levels were significantly lower in hypertensive (nâ=â21) than normotensive cases (nâ=â64), perhaps translating to decreased Aß catabolism in hypertensives. ACE level was significantly higher in treated (nâ=â9) than untreated hypertensives (nâ=â12), possibly reflecting feedback upregulation of the renin-angiotensin system. Prospective studies in larger cohorts stratified according to anti-hypertensive drug class are needed to confirm these initial findings and to elucidate the interactions between hypertension, anti-hypertensive treatments, and Aß metabolism.
Asunto(s)
Secretasas de la Proteína Precursora del Amiloide/metabolismo , Antihipertensivos/uso terapéutico , Lóbulo Frontal/patología , Hipertensión/patología , Placa Amiloide/patología , Anciano , Anciano de 80 o más Años , Femenino , Lóbulo Frontal/efectos de los fármacos , Lóbulo Frontal/metabolismo , Humanos , Hipertensión/tratamiento farmacológico , Hipertensión/metabolismo , Inmunohistoquímica , Insulisina/metabolismo , Masculino , Neprilisina/metabolismo , Peptidil-Dipeptidasa A/metabolismo , Placa Amiloide/tratamiento farmacológico , Placa Amiloide/metabolismo , Estudios RetrospectivosRESUMEN
BACKGROUND: Higher angiotensin-converting enzyme (ACE) activity might increase the risk of Alzheimer's disease by increasing blood pressure, and subsequent development of cerebral small vessel disease (CSVD). Yet, it may also decrease this risk, as it functions to degrade amyloid-ß, thereby reducing brain atrophy. OBJECTIVE: To examine the cross-sectional associations of serum and cerebrospinal fluid (CSF) ACE protein levels and activity with brain atrophy and CSVD in a memory clinic cohort. METHODS: In 118 subjects from the memory clinic based Amsterdam Dementia Cohort (mean age 66 ± 8 years), ACE protein levels (ng/ml) and activity in CSF and serum were investigated. Poisson regression analyses were used to associate ACE measurements with rated global cortical atrophy, medial temporal lobe atrophy, lacunar infarcts, white matter hyperintensities, and microbleeds on brain MRI. RESULTS: Higher CSF ACE activity was associated with a reduced risk of global brain atrophy. The relative risk (95% CI) of having global cortical atrophy ≥2 per SD increase in CSF ACE activity was 0.67 (0.49; 0.93). ACE levels were not significantly related to measures of CSVD. CONCLUSIONS: These results show that high ACE might have protective effects on the brain. This could suggest that ACE inhibitors, which may lower CSF ACE levels, are not preferred as antihypertensive treatment in patients at risk for Alzheimer's disease.
Asunto(s)
Enfermedad de Alzheimer/líquido cefalorraquídeo , Enfermedad de Alzheimer/patología , Encefalopatías/líquido cefalorraquídeo , Encefalopatías/patología , Encéfalo/patología , Peptidil-Dipeptidasa A/líquido cefalorraquídeo , Anciano , Anciano de 80 o más Años , Enfermedad de Alzheimer/sangre , Apolipoproteínas E/genética , Atrofia/líquido cefalorraquídeo , Atrofia/patología , Encefalopatías/sangre , Enfermedades de los Pequeños Vasos Cerebrales/enzimología , Femenino , Humanos , Imagen por Resonancia Magnética , Masculino , Trastornos de la Memoria/líquido cefalorraquídeo , Trastornos de la Memoria/etiología , Persona de Mediana Edad , Peptidil-Dipeptidasa A/sangreRESUMEN
INTRODUCTION: Lower angiotensin-converting enzyme (ACE) activity could increase the risk of Alzheimer's disease (AD) as ACE functions to degrade amyloid-ß (Aß). Therefore, we investigated whether ACE protein and activity levels in cerebrospinal fluid (CSF) and serum were associated with CSF Aß, total tau (tau) and tau phosphorylated at threonine 181 (ptau). METHODS: We included 118 subjects from our memory clinic-based Amsterdam Dementia Cohort (mean age 66 ± 8 years) with subjective memory complaints (n = 40) or AD (n = 78), who did not use antihypertensive drugs. We measured ACE protein levels (ng/ml) and activity (RFU) in CSF and serum, and amyloid ß1-42, tau and ptau (pg/ml) in CSF. RESULTS: Cross-sectional regression analyses showed that ACE protein level and activity in CSF and serum were lower in patients with AD compared to controls. Lower CSF ACE protein level, and to a lesser extent serum ACE protein level and CSF ACE activity, were associated with lower CSF Aß, indicating more brain Aß pathology; adjusted regression coefficients (B) (95% CI) per SD increase were 0.09 (0.04; 0.15), 0.06 (0.00; 0.12) and 0.05 (0.00; 0.11), respectively. Further, lower CSF ACE protein level was associated with lower CSF tau and ptau levels; adjusted B's (95% CI) per SD increase were 0.15 (0.06; 0.25) and 0.17 (0.10; 0.25), respectively. CONCLUSIONS: These results strengthen the hypothesis that ACE degrades Aß. This could suggest that lowering ACE levels by for example ACE-inhibitors might have adverse consequences for patients with, or at risk for AD.
RESUMEN
Decreased cerebral blood flow and blood-brain barrier disruption are features of Alzheimer's disease (AD). The plasma kallikrein-kinin system modulates cerebrovascular tone through release of vasoactive bradykinin (BK). Cerebroventricular infusion of Aß1-40 enhances BK release, suggesting that the activity of this system may be elevated in AD. We investigated the profile of the activating protease of this system, plasma kallikrein (PK), in frontal and temporal brain tissue from postmortem confirmed cases of AD, vascular dementia (VaD), and controls. Measurements of neuron specific enolase messenger ribonucleic acid (mRNA) and protein were used to adjust for neuronal loss. Adjusted PK mRNA was significantly increased in the frontal cortex in AD, and the frontal and temporal cortex in VaD. Similar trends were seen for PK protein level in AD and VaD. PK activity was significantly increased in the frontal and temporal cortex in AD. Increased PK activity in AD is likely to contribute to increased BK release and may thereby influence cerebral blood flow and vascular permeability.
Asunto(s)
Enfermedad de Alzheimer/metabolismo , Demencia Vascular/metabolismo , Lóbulo Frontal/metabolismo , Sistema Calicreína-Quinina/fisiología , Lóbulo Temporal/metabolismo , Anciano , Anciano de 80 o más Años , Enfermedad de Alzheimer/sangre , Enfermedad de Alzheimer/enzimología , Bradiquinina/sangre , Bradiquinina/metabolismo , Estudios de Cohortes , Demencia Vascular/sangre , Demencia Vascular/enzimología , Femenino , Lóbulo Frontal/enzimología , Humanos , Calicreínas/sangre , Calicreínas/metabolismo , Masculino , Persona de Mediana Edad , Lóbulo Temporal/enzimologíaRESUMEN
Human kallikrein-related peptidase 6 (KLK6) is highly expressed in the central nervous system. Although the physiological roles of this serine protease are unknown, in vitro substrates include amyloid precursor protein and components of the extracellular matrix, which are altered in neurological disease, particularly Alzheimer's disease (AD). We have compared KLK6 expression in post-mortem brain tissue in AD, vascular dementia (VaD) and controls. We studied the distribution of KLK6 in the temporal cortex and white matter by immunohistochemistry, and measured KLK6 mRNA and protein levels in the frontal and temporal cortex from 15 AD, 15 VaD and 15 control brains. Immunohistochemistry showed KLK6 to be restricted to endothelial cells. After adjustment for variations in vessel density by measurement of factor VIII-related antigen, we found KLK6 protein and mRNA levels to be significantly decreased in the frontal but not the temporal cortex in AD. In VaD, KLK6 protein level was significantly increased in the frontal cortex. Our findings suggest that an altered KLK6 expression may contribute to vascular abnormalities in AD and VaD.